

5 February 2026

Unilever PLC
(the "Company")

Notification of issuance of equity securities

4,200,000 ordinary shares of 3 1/2p each in the Company (the "New Ordinary Shares") have been issued and allotted for the purposes of satisfying the vesting of awards under the Company's employee share schemes (the Unilever Share Plan 2017 (including the Unilever North America Omnibus Equity Compensation Plan) and the SHARES Plan) and admitted to trading on the Main Market of the LSE under the Company's existing block admission of shares for this purpose dated 14 March 2024.

The New Ordinary Shares will rank equally with the existing issued ordinary shares of the Company.

This notification is being made in accordance with UKLR 6.4.4 and PRM 1.6.2, and for PRM 1.6.2 purposes covers the period 15 September 2025 to 5 February 2026.

1 Details of the issuer		
a)	Name	Unilever PLC
b)	LEI	549300MKFYEKVRWML317
2 Details of the transferable securities issued and admitted to trading		
a)	Name, type and identification code	Unilever PLC ordinary 3 1/2 pence shares GB00BVZK7T90
b)	Regulated market	London Stock Exchange - Main Market
c)	Number of further securities issued and admitted	4,200,000
d)	Total number of securities admitted following issuance	2,185,205,247 ordinary shares 1,577,778 ordinary shares (not yet in issue) remain subject to the block admission dated 14 March 2024
e)	Fungibility	Fully fungible with existing ordinary shares
3 Issue and admission details		
a)	Dates of issuance and admission	5 February 2026 (admitted under block admission dated 14 March 2024)
b)	Prospectus information	Prospectus: N/A Supplementary: N/A Company's website: https://www.unilever.com/

For any enquiries, please contact:

Investor Relations: Investor.Relations@unilever.com

Unilever Press Office: Press-Office.London@unilever.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seq.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOEGZGGZVKFGVZM